Answers are grounded in this paper and cite their sources.
Analysis of genomic therapy matching shows improved survival in rare cancers with clinical support, indicating potential treatment pathways.
To the Editor Lin et al1 report an important analysis of genomic therapy matching in rare and refractory cancers. The finding that improved survival was seen with clinically supported matches but not with investigational tiers is particularly interesting and clinically relevant.
No takes yet. Share an insight, caveat, or question.
Polina Shilo (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: